About this medication
Different FDA-approved GLP-1 and GIP-based products have different labeled indications. This refill pathway focuses on continuity of established therapy, not automatic initiation, dose escalation, or product switching.
Insurance and coverage
Insurance coverage varies by product, indication, and plan. BCBSTX PPO patients can start with coverage verification rather than paying $39 upfront.
Using BCBSTX insurance? Start here
Which established medications may be evaluated?
Semaglutide
Established semaglutide continuation, including brand-specific pathways when appropriate.
Tirzepatide
Established tirzepatide continuation for appropriate patients.
Ozempic
Established Ozempic maintenance refill evaluation.
Wegovy
Established Wegovy injection or oral-tablet continuation, when clinically appropriate.
Mounjaro
Established Mounjaro maintenance refill evaluation.
Zepbound
Established Zepbound maintenance refill evaluation.
Foundayo
Established oral orforglipron weight-management continuation.
What should I have ready?
- Medication name and current dose
- How long you have been taking it
- Date of your last dose
- Current weight and recent weight trend
- Original indication and prior prescriber information
- Recent A1C/glucose data if used for diabetes
- Side effects and relevant medical history
- Photo of current prescription packaging when available
This is a maintenance-refill pathway, not automatic continuation
To continue therapy, you'll need to show you're already taking this medication, such as a pharmacy label, prior prescription, or records from your prescriber. New starts, restarts after a long gap, or dose increases require a broader evaluation and may not be completed through this refill pathway.
When might GLP-1 continuation not be appropriate through a routine refill visit?
Examples include severe or persistent abdominal pain, repeated vomiting or dehydration, suspected pancreatitis, significant gallbladder symptoms, pregnancy, severe medication reactions, major recent dose changes, or other unstable symptoms. Emergency symptoms require urgent or emergency care.
Insurance and pharmacy availability
The $39 fee is for the clinical evaluation. It does not include medication cost, guarantee insurance authorization, or guarantee that a specific pharmacy has the medication in stock.
Compounded products
Americare evaluates FDA-approved GLP-1 and GIP products only. We do not prescribe compounded semaglutide, compounded tirzepatide, or other compounded GLP-1 products.